State of New Jersey Common Pension Fund D Has $2.27 Million Stock Holdings in Repligen Corporation $RGEN

State of New Jersey Common Pension Fund D raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,252 shares of the biotechnology company’s stock after purchasing an additional 326 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Repligen were worth $2,270,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Twin Tree Management LP acquired a new stake in shares of Repligen during the first quarter worth $29,000. Signaturefd LLC raised its stake in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 128 shares in the last quarter. AlphaQuest LLC acquired a new position in Repligen in the second quarter valued at about $104,000. GAMMA Investing LLC raised its stake in Repligen by 40.1% in the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 274 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new position in Repligen in the first quarter valued at about $132,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $151.57 on Wednesday. The stock’s 50 day moving average is $133.89 and its 200-day moving average is $128.45. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The firm has a market capitalization of $8.53 billion, a price-to-earnings ratio of -606.26, a PEG ratio of 3.56 and a beta of 1.08. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.Repligen’s quarterly revenue was up 21.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RGEN. Evercore ISI lifted their target price on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Wall Street Zen upgraded Repligen from a “hold” rating to a “buy” rating in a report on Monday. Finally, Wells Fargo & Company reduced their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $171.54.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.